Mader RM - Search Results

1

Tissue distribution of epirubicin after severe extravasation in humans.

Nedomansky J, Haslik W, Pluschnig U, Kornauth C, Deutschmann C, Hacker S, Steger GG, Bartsch R, Mader RM. Nedomansky J, et al. Among authors: mader rm. Cancer Chemother Pharmacol. 2021 Aug;88(2):203-209. doi: 10.1007/s00280-021-04280-8. Epub 2021 Apr 27. Cancer Chemother Pharmacol. 2021. PMID: 33907881 Free PMC article.

2

Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses.

Steger GG, Wrba F, Mader R, Schlappack O, Dittrich C, Rainer H. Steger GG, et al. Eur J Cancer. 1991;27(3):254-6. doi: 10.1016/0277-5379(91)90509-c. Eur J Cancer. 1991. PMID: 1827307

3

Instability of the anticancer agent etoposide under in vitro culture conditions.

Mader RM, Steger GG, Moser K, Rainer H, Krenmayr P, Dittrich C. Mader RM, et al. Cancer Chemother Pharmacol. 1991;27(5):354-60. doi: 10.1007/BF00688857. Cancer Chemother Pharmacol. 1991. PMID: 1998995

4

Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.

Steger GG, Dittrich C, Schlappack O, Mader R, Herold C, Brade WP, Keller A, Moser K. Steger GG, et al. J Cancer Res Clin Oncol. 1988;114(6):602-4. doi: 10.1007/BF00398184. J Cancer Res Clin Oncol. 1988. PMID: 3144554

5

Poly(I).poly(C), a potential drug carrier for the antitumor agent mitoxantrone: in vitro drug binding study.

Eichler HG, Mader R, Blöchl-Daum B, Steger G, Rainer H. Eichler HG, et al. Cancer Chemother Pharmacol. 1987;20(1):81-2. doi: 10.1007/BF00252966. Cancer Chemother Pharmacol. 1987. PMID: 3621457

6

Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.

Mader RM, Zilg H, Schlappack O, Steger GG, Baur M, Greifenberg B, Heberle U, Dittrich C. Mader RM, et al. Cancer Chemother Pharmacol. 1995;37(1-2):91-6. doi: 10.1007/BF00685634. Cancer Chemother Pharmacol. 1995. PMID: 7497603 Clinical Trial.

7

Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity?

Locker GJ, Simonitsch I, Mader RM, Warlamides E, Gnant MF, Jakesz R, Rainer H, Steger GG. Locker GJ, et al. Among authors: mader rm. Breast Cancer Res Treat. 1995 Jun;34(3):213-9. doi: 10.1007/BF00689712. Breast Cancer Res Treat. 1995. PMID: 7579485 Clinical Trial.

8

Different stereospecific protein binding of tetrahydrofolates to human serum albumin.

Mader RM, Steger GG, Rizovski B, Jakesz R, Rainer H. Mader RM, et al. J Pharm Sci. 1994 Sep;83(9):1247-9. doi: 10.1002/jps.2600830912. J Pharm Sci. 1994. PMID: 7830239

9

New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer.

Locker GJ, Mader RM, Braun J, Sieder AE, Marosi C, Rainer H, Jakesz R, Steger GG. Locker GJ, et al. Among authors: mader rm. Oncology. 1995 Mar-Apr;52(2):140-4. doi: 10.1159/000227445. Oncology. 1995. PMID: 7854774

10

Comparison of an immunoradiometric and an immunoluminometric assay for the evaluation of the tumour associated antigens CA 19-9 and CA 125.

Mader RM, Steger GG, Braun J, Rainer H. Mader RM, et al. Eur J Clin Chem Clin Biochem. 1994 Feb;32(2):85-90. doi: 10.1515/cclm.1994.32.2.85. Eur J Clin Chem Clin Biochem. 1994. PMID: 8003582

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

208 results

Search Page

Filters